We are live on ! Find out more
JGUA

John G. Ullman & Associates Portfolio holdings

AUM $754M
1-Year Est. Return 60.05%
This Fund
S&P 500
This Quarter Est. Return
+8.51%
1 Year Est. Return
+60.05%
3 Year Est. Return
+108.28%
5 Year Est. Return
+118.76%
10 Year Est. Return
+308.24%
AUM
$524M
AUM Growth
+$32.8M
Cap. Flow
-$6.68M
Cap. Flow %
-1.28%
Top 10 Hldgs %
32.2%
Holding
157
New
6
Increased
38
Reduced
96
Closed
8

Top Buys

Rank Stock Value
1
IBM icon
IBM
IBM
+$3.58M
2
ITRI icon
Itron
ITRI
+$1.9M
3
LLY icon
Eli Lilly
LLY
+$1.83M
4
LNN icon
Lindsay Corp
LNN
+$1.79M
5
EME icon
Emcor
EME
+$1.22M

Sector Composition

Rank Sector Weight
1 Healthcare 24.97%
2 Industrials 17.47%
3 Technology 16.95%
4 Energy 9%
5 Utilities 8.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DAR icon
151
Darling Ingredients
DAR
$9.63B
-77,750
Closed -$1.65M
DGX icon
152
Quest Diagnostics
DGX
$25.8B
-3,636
Closed -$225K
PGJ icon
153
Invesco Golden Dragon China ETF
PGJ
$97.3M
-56,100
Closed -$1.61M
RBBN icon
154
Ribbon Communications
RBBN
$380M
-2,000
Closed -$34K
TLAB
155
DELISTED
TELLABS INC
TLAB
-25,000
Closed -$57K
XIDE
156
DELISTED
EXIDE TECHNOLOGIES NEW COM
XIDE
-10,000
Closed -$4K
BZF
157
DELISTED
WisdomTree Brazilian Real Strategy Fund
BZF
-32,550
Closed -$590K

Similar funds

John G. Ullman & Associates's Q4 2013 Portfolio in Review

As of Q4 2013, John G. Ullman & Associates held 157 positions worth $524M, up 6.7% from $491M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

John G. Ullman & Associates's Q4 2013 filing shows 6 new, 38 increased, 96 reduced and 8 closed positions. Its largest new stake was Emcor: 31,300 shares worth $1.33M. The largest sale was Bristol-Myers Squibb, an estimated $2.98M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier, followed by Industrials and Technology.

  • John G. Ullman & Associates's largest Q4 2013 buy was Emcor: 31,300 shares worth $1.33M.
  • John G. Ullman & Associates added most to IBM in Q4 2013, an estimated $3.58M increase.
  • John G. Ullman & Associates's biggest Q4 2013 reduction was Bristol-Myers Squibb, cutting an estimated $2.98M.
  • John G. Ullman & Associates fully exited Darling Ingredients in Q4 2013, selling an estimated $1.65M.
  • John G. Ullman & Associates's ten largest holdings make up 32% of its $524M portfolio in Q4 2013.
  • John G. Ullman & Associates opened 6 new positions and closed 8 in Q4 2013.
  • John G. Ullman & Associates's portfolio value rose 6.7% quarter-over-quarter to $524M.

Based on John G. Ullman & Associates's 13F filing for Q4 2013, filed 3 Feb 2014.